Arday D R, Kanjarpane D D, Kelley P W
Department of Advanced Preventive Medicine Studies, Walter Reed Army Institute of Research, Washington, DC 20307.
Am J Public Health. 1989 Apr;79(4):471-4. doi: 10.2105/ajph.79.4.471.
The US Army's experience with mumps hospitalizations was examined for the years 1980 through 1986. One hundred fifty-two cases among active duty Army soldiers were identified. Mumps rates declined from 3.85 per 100,000 active duty soldiers per year in 1980 to 1.28 in 1985, but an outbreak during 1986 caused rates to jump to 6.65. Attack rates were found to decline dramatically with increasing age or length of military service, with 74 per cent of cases occurring in soldiers with three years or less of service. Rates for Blacks and Whites were similar, but were higher for other minorities. Complications reported were mild. A cost-benefit analysis, assuming all recruits were to be vaccinated, estimated average annual vaccination program costs of $286,789; this figure exceeds average annual reported hospitalized mumps disease costs of $61,525 by a factor of 4.7. Mumps attack rates would have to reach at least 15.0 per 100,000 per year before savings would equal recruit vaccination costs. Failure to show that a vaccine program would be cost-saving may be due to limitations in identifying cases or to the requirement that all recruits be immunized regardless of prior immune status. It is likely that a program to immunize susceptible individuals alone would show benefit.
对美国陆军1980年至1986年期间腮腺炎住院情况进行了调查。在现役陆军士兵中确认了152例病例。腮腺炎发病率从1980年的每年每10万名现役士兵3.85例降至1985年的1.28例,但1986年的一次疫情使发病率跃升至6.65例。研究发现,发病率随着年龄增长或服役年限增加而大幅下降,74%的病例发生在服役三年及以下的士兵中。黑人和白人的发病率相似,但其他少数族裔的发病率更高。报告的并发症较轻。一项成本效益分析假设所有新兵都接种疫苗,估计疫苗接种计划的年均成本为286,789美元;这一数字比报告的腮腺炎住院疾病年均成本61,525美元高出4.7倍。腮腺炎发病率每年至少要达到每10万人15.0例,节省的费用才会等于新兵接种疫苗的成本。未能证明疫苗接种计划具有成本效益,可能是由于病例识别方面的限制,或者是由于要求所有新兵无论之前的免疫状况如何都要接种疫苗。仅对易感个体进行免疫接种的计划可能会显示出益处。